echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > FDA approved another Pfizer targeted anticancer drug, acetinib

    FDA approved another Pfizer targeted anticancer drug, acetinib

    • Last Update: 2012-01-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: China Council for the promotion of drugs 2012-01-29 the U.S Food and drug administration has sealed and approved the new kidney cancer drug axitinib of Pfizer Pharmaceutical giant Pfizer plans to list the drug under the name of inlyta The FDA's approval marks Pfizer's victory in targeting anti-cancer drug research and development Last year, xalkori, a non-small cell lung cancer drug targeting patients with ALK gene mutation, won the FDA's approval The approved inlyta is a selective vascular endothelial growth factor (VEGF) inhibitor Pfizer's tests on 723 patients showed that the median progression free survival time of the drug was 6.7 months, which was longer than the 4.7 months of patients taking Onyx drug dorgime (sorafenib) Pfizer has a new horse in the crowded market competition for advanced renal cancer drugs Since the approval of sorafenib in 2005, seven renal cancer drugs have been approved in the United States, according to the FDA Pfizer is also selling two other advanced kidney cancer drugs, SUTENT and Torisel Lecheng pharmaceutical is planning to get approval for its VEGF inhibitor tivozanib in the treatment of renal cancer In this way, Pfizer and Lucheng's horses will compete in targeting multiple VEGF receptors According to Pfizer, FDA is using Pfizer's inlyta for patients who fail to receive systematic treatment Lucheng, headquartered in Cambridge, Massachusetts, has an ambitious plan to win FDA approval for tivozanib as a first-line treatment for advanced renal cancer Despite the competition in this market, in order to meet the needs of special patients, FDA expressed support for Pfizer CEO Ian Reid's plan to focus the pharmaceutical company's R & D efforts on targeted drugs and add another commercial product to the company's roster to make up for the reduced revenue brought by generic drugs Original link: http://
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.